<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718883</url>
  </required_header>
  <id_info>
    <org_study_id>JWCAR029-005</org_study_id>
    <nct_id>NCT04718883</nct_id>
  </id_info>
  <brief_title>CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ming Ju Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Ming Ju Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open-label, single-arm, multicenter study to assess the efficacy and&#xD;
      safety of JWCAR029 in adult R/R Mantle Cell Lymphoma subjects in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, open-label, single-arm, multicenter study conducted in adult subjects&#xD;
      with relapsed and refractory (R/R) mantle cell lymphoma (MCL) in China to evaluate the&#xD;
      safety, efficacy, pharmacokinetics(PK), pharmacodynamics(PD) of JWCAR029 and immune response&#xD;
      after JWCAR029 treatment.&#xD;
&#xD;
      R/R MCL patients will be enrolled in dose level of 1.0 x 10^8 CAR+ T cells. All subjects will&#xD;
      be followed for 2 years following JWCAR029 infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>Objective response rate (ORR) in 3 month in relapsed and refractory (R/R) mantle cell lymphoma (MCL) subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CRR)</measure>
    <time_frame>3 months</time_frame>
    <description>Complete response rate (CRR) in 3 month in relapsed and refractory (R/R) mantle cell lymphoma (MCL) subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The best objective response rate</measure>
    <time_frame>3 months</time_frame>
    <description>The best objective response rate in 3 month in relapsed and refractory (R/R) mantle cell lymphoma (MCL) subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The best complete response rate</measure>
    <time_frame>3 months</time_frame>
    <description>The best complete response rate in 3 month in relapsed and refractory (R/R) mantle cell lymphoma (MCL) subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of adverse events (AEs)</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Type of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events(AEs)</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Number of participants with laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of laboratory abnormalities</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Type of laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of laboratory abnormalities</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Severity of laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from first response(PR or CR) to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete remission (DoCR)</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from complete response (CR) to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of partial remission (DoPR)</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from partial response (PR) to disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from JWCAR029 infusion to first documentation of complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete response (TTCR)</measure>
    <time_frame>Up to 24 months after JWCAR029 infusion</time_frame>
    <description>Time from JWCAR029 infusion to first documentation of complete response (CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of JWCAR029</measure>
    <time_frame>Up to 1 year after JWCAR029 infusion</time_frame>
    <description>Maximum observed concentration of JWCAR029 in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of JWCAR029:</measure>
    <time_frame>Up to 1 year after JWCAR029 infusion</time_frame>
    <description>Time to maximum concentration of JWCAR029 in the peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of JWCAR029:</measure>
    <time_frame>Up to 1 year after JWCAR029 infusion</time_frame>
    <description>Area under the concentration vs time curve of JWCAR029 in the peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-therapeutic JWCAR029 antibody</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>Anti-therapeutic JWCAR029 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of T cell counts</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>Changes of T cell counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Subgroups of T cell</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>Changes of Subgroups of T cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of serum cytokines</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>Changes of serum cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD19 expression in tumor biopsy samples</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>CD19 expression in tumor biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory biomarkers such as CRP</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>Changes in inflammatory biomarkers such as CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory biomarkers such as ferritin</measure>
    <time_frame>Up to 2 year after JWCAR029 infusion</time_frame>
    <description>Changes in inflammatory biomarkers such as CRP</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>JWCAR029 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JWCAR029 be administrated at dose level: 1 x 10^8 CAR+T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-targeted Chimeric Antigen Receptor (CAR) T Cells</intervention_name>
    <description>JWCAR029 will be administered at dose level: 1 x 10^8 CAR+T cells</description>
    <arm_group_label>JWCAR029 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old;&#xD;
&#xD;
          -  Sign on the informed consent;&#xD;
&#xD;
          -  Subject must have histologically confirmed mantle cell lymphoma;&#xD;
&#xD;
          -  Relapsed/refractory patients;&#xD;
&#xD;
          -  Subjects have accessible PET-positive lesion and have measurable CT-positive lesion&#xD;
             according to Lugano Classification;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
          -  Expected survival is greater than 12 weeks;&#xD;
&#xD;
          -  Adequate organ function;&#xD;
&#xD;
          -  Adequate vascular access for leukapheresis procedure;&#xD;
&#xD;
          -  Subjects who have previously received CD19 targeted therapy must confirm that lymphoma&#xD;
             lesions still express CD19;&#xD;
&#xD;
          -  Women of childbearing potential must agree to use highly effective methods of&#xD;
             contraception for 1 year after the last dose of JWCAR029;&#xD;
&#xD;
          -  Males who have partners of childbearing potential must agree to use an effective&#xD;
             barrier contraceptive method for 1 year after the last dose of JWCAR029.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system (CNS) only involvement by malignancy or primary CNS lymphoma;&#xD;
&#xD;
          -  History of another primary malignancy that has not been in remission for at least 2&#xD;
             years;&#xD;
&#xD;
          -  Subjects has HBV, HCV, HIV or syphilis infection at the time of screening;&#xD;
&#xD;
          -  Deep venous thrombosis (DVT)/Pulmonary embolism (PE), or DVT/PE requires&#xD;
             anti-coagulation within 3 months prior to signing the ICF;&#xD;
&#xD;
          -  Subjects with uncontrolled systemic fungal, bacterial, viral or other infection;&#xD;
&#xD;
          -  Presence of acute or chronic graft-versus-host disease (GVHD);&#xD;
&#xD;
          -  History of any serious cardiovascular disease or presence of clinically relevant CNS&#xD;
             pathology;&#xD;
&#xD;
          -  Pregnant or nursing women;&#xD;
&#xD;
          -  Subjects using of any chemotherapy, corticosteriod, experiment agents, GVHD therapies,&#xD;
             radiation or any other therapies for lymphoma must go through a specific wash-out&#xD;
             period before leukapheresis;&#xD;
&#xD;
          -  Received allo-hematopoietic stem cell transplantation therapy previously.&#xD;
&#xD;
          -  Uncontrolled conditions or unwillingness or inability to follow the procedures&#xD;
             required in the protocol;&#xD;
&#xD;
          -  Received CAR T-cell or other genetically-modified T-cell therapy previously.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JWCAR029 Medical</last_name>
    <phone>+86 21 50464201</phone>
    <email>JWCAR029Medical@jwtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei Jing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Consonancy Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianda Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Province people hospital</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WenYu Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Province Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keshu Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province People Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyong Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junning Cao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dehui Zou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanfang Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang province Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Yang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JWCAR029</keyword>
  <keyword>B-Cell Malignancies</keyword>
  <keyword>Non-Hodgkin lymphoma</keyword>
  <keyword>CAR T cells</keyword>
  <keyword>Chimeric antigen receptor</keyword>
  <keyword>Relapsed/Refractory</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

